Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2025-12-25 @ 9:48 PM
Study NCT ID:
NCT07293351
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-19
First Post:
2025-12-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002292', 'term': 'Carcinoma, Renal Cell'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D007680', 'term': 'Kidney Neoplasms'}, {'id': 'D014571', 'term': 'Urologic Neoplasms'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000074324', 'term': 'Ipilimumab'}, {'id': 'C558660', 'term': 'cabozantinib'}, {'id': 'D000077594', 'term': 'Nivolumab'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 264}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-03-26', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2031-11-26', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-17', 'studyFirstSubmitDate': '2025-12-17', 'studyFirstSubmitQcDate': '2025-12-17', 'lastUpdatePostDateStruct': {'date': '2025-12-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-12-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2029-11-28', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with adverse events (AEs)', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 1'}, {'measure': 'Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5))', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 1'}, {'measure': 'Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria', 'timeFrame': 'Up to day 21 from first dose', 'description': 'Phase 1'}, {'measure': 'Number of participants with AEs leading to discontinuation', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 1'}, {'measure': 'Number of participants with AEs leading to death', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 1'}, {'measure': 'Objective response rate (ORR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}], 'secondaryOutcomes': [{'measure': 'Number of participants with AEs', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}, {'measure': 'Number of participants with SAEs (as per CTCAE v5)', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}, {'measure': 'Number of participants with treatment-related adverse events (TRAEs)', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}, {'measure': 'Number of participants with AEs leading to discontinuation', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}, {'measure': 'Number of participants with AEs leading to death', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}, {'measure': 'Progression-free survival (PFS) by RECIST v1.1 per investigator assessment', 'timeFrame': 'Up to 4 years from randomization', 'description': 'Phase 2'}, {'measure': 'Duration of response (DOR) (PR or CR) by RECIST v1.1 per investigator assessment', 'timeFrame': 'Up to approximately 2 years from end of treatment', 'description': 'Phase 2'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Renal Cell Carcinoma', 'Cabozantinib', 'Pumitamig', 'Ipilmumab', 'Nivolumab'], 'conditions': ['Advanced Renal Cell Carcinoma (RCC)']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html', 'label': 'BMS Clinical Trial Information'}, {'url': 'https://www.BMSClinicalTrials.com', 'label': 'BMS Clinical Trial Patient Recruiting'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not amenable to curative surgery or radiation therapy) or metastatic Renal Cell Carcinoma (RCC).\n* Participants must have clear cell RCC (ccRCC) or non-clear cell RCC (nccRCC) may be enrolled in Part 1. Note: Part 2 may only enroll participants with ccRCC.\n* Participants may have favorable, intermediate or poor risk disease categories.\n* Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:\n\n i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.\n\nii) For Part 1A participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received any therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., ipilimumab).\n\niii) For Part 1B participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with cabozantinib.\n\n\\- Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\nExclusion Criteria\n\n* Participants must not have any untreated known CNS metastases.\n* Participants must not have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of Cycle 1 Day1 (C1D1).\n* Participants must not have a history of interstitial lung disease or pneumonitis.\n* Participants must not have an uncontrolled pleural or pericardial effusion requiring recurrent therapeutic drainage procedures.\n* Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to C1D1, uncontrolled hypertension (≥ 150 systolic, ≥ 90 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.\n* Participants must not have a urine protein ≥ 2+ and 24 hour urine protein ≥ 1 g at baseline.\n* Participants must not have evidence of major coagulation disorders.\n* Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 6 months prior to C1D1.\n* Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months.\n* Participants must not have had a major surgery or trauma within 28 days prior to C1D1.\n* Other protocol-defined Inclusion/Exclusion criteria apply.'}, 'identificationModule': {'nctId': 'NCT07293351', 'briefTitle': 'A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bristol-Myers Squibb'}, 'officialTitle': 'ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)', 'orgStudyIdInfo': {'id': 'CA266-0008'}, 'secondaryIdInfos': [{'id': '2025-523637-26', 'type': 'OTHER', 'domain': 'EU CT Number'}, {'id': 'U1111-1327-6332', 'type': 'OTHER', 'domain': 'UTN'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part 1A: Arm A', 'interventionNames': ['Drug: Pumitamig', 'Drug: Ipilimumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1A: Arm B', 'interventionNames': ['Drug: Pumitamig', 'Drug: Ipilimumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1B: Arm G', 'interventionNames': ['Drug: Pumitamig', 'Drug: Cabozantinib']}, {'type': 'EXPERIMENTAL', 'label': 'Part 1B: Arm H', 'interventionNames': ['Drug: Pumitamig', 'Drug: Cabozantinib']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2A: Arm C', 'interventionNames': ['Drug: Pumitamig', 'Drug: Ipilimumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2A: Arm D', 'interventionNames': ['Drug: Pumitamig', 'Drug: Ipilimumab']}, {'type': 'OTHER', 'label': 'Part 2A: Arm E', 'interventionNames': ['Drug: Ipilimumab', 'Drug: Nivolumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2A: Arm F', 'interventionNames': ['Drug: Pumitamig']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2B: Arm I', 'interventionNames': ['Drug: Pumitamig', 'Drug: Cabozantinib']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2B: Arm J', 'interventionNames': ['Drug: Pumitamig', 'Drug: Cabozantinib']}, {'type': 'OTHER', 'label': 'Part 2B: Arm K', 'interventionNames': ['Drug: Nivolumab']}, {'type': 'EXPERIMENTAL', 'label': 'Part 2B: Arm L', 'interventionNames': ['Drug: Pumitamig']}], 'interventions': [{'name': 'Pumitamig', 'type': 'DRUG', 'otherNames': ['BMS-986545'], 'description': 'Specified dose on specified days', 'armGroupLabels': ['Part 1A: Arm A', 'Part 1A: Arm B', 'Part 1B: Arm G', 'Part 1B: Arm H', 'Part 2A: Arm C', 'Part 2A: Arm D', 'Part 2A: Arm F', 'Part 2B: Arm I', 'Part 2B: Arm J', 'Part 2B: Arm L']}, {'name': 'Ipilimumab', 'type': 'DRUG', 'otherNames': ['Yervoy'], 'description': 'Specified dose on specified days', 'armGroupLabels': ['Part 1A: Arm A', 'Part 1A: Arm B', 'Part 2A: Arm C', 'Part 2A: Arm D', 'Part 2A: Arm E']}, {'name': 'Cabozantinib', 'type': 'DRUG', 'description': 'Specified dose on specified days', 'armGroupLabels': ['Part 1B: Arm G', 'Part 1B: Arm H', 'Part 2B: Arm I', 'Part 2B: Arm J']}, {'name': 'Nivolumab', 'type': 'DRUG', 'otherNames': ['Opdivo'], 'description': 'Specified dose on specified days', 'armGroupLabels': ['Part 2A: Arm E', 'Part 2B: Arm K']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06510', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'contacts': [{'name': 'Site 0117', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0117', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '20016', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'contacts': [{'name': 'Site 0134', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0134', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'contacts': [{'name': 'Site 0126', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0126', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'contacts': [{'name': 'Site 0124', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0124', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'contacts': [{'name': 'Site 0123', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0123', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'contacts': [{'name': 'Site 0094', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0094', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '11788', 'city': 'Hauppauge', 'state': 'New York', 'country': 'United States', 'contacts': [{'name': 'Site 0096', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0096', 'geoPoint': {'lat': 40.82565, 'lon': -73.20261}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'contacts': [{'name': 'Site 0127', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0127', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'contacts': [{'name': 'Site 0165', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0165', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '29572', 'city': 'Myrtle Beach', 'state': 'South Carolina', 'country': 'United States', 'contacts': [{'name': 'Site 0114', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0114', 'geoPoint': {'lat': 33.68906, 'lon': -78.88669}}, {'zip': '84112', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Local Institution - 0158', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '98109-1023', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'contacts': [{'name': 'Site 0095', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0095', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '1426', 'city': 'Buenos Aires', 'country': 'Argentina', 'contacts': [{'name': 'Site 0154', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0154', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1199ABB', 'city': 'Buenos Aires', 'country': 'Argentina', 'contacts': [{'name': 'Site 0156', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0156', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '2109', 'city': 'North Ryde', 'state': 'New South Wales', 'country': 'Australia', 'contacts': [{'name': 'Site 0076', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0076', 'geoPoint': {'lat': -33.79677, 'lon': 151.12436}}, {'zip': '2065', 'city': 'St Leonards', 'state': 'New South Wales', 'country': 'Australia', 'contacts': [{'name': 'Site 0111', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0111', 'geoPoint': {'lat': -33.82344, 'lon': 151.19836}}, {'zip': '4101', 'city': 'South Brisbane', 'state': 'Queensland', 'country': 'Australia', 'contacts': [{'name': 'Site 0074', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0074', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '3144', 'city': 'Malvern', 'country': 'Australia', 'contacts': [{'name': 'Site 0003', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0003', 'geoPoint': {'lat': -37.86259, 'lon': 145.02811}}, {'zip': '70200-730', 'city': 'Brasília', 'state': 'Federal District', 'country': 'Brazil', 'contacts': [{'name': 'Site 0093', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0093', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'zip': 'T2N 4N2', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'contacts': [{'name': 'Site 0007', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0007', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'H2L 4M1', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'contacts': [{'name': 'Site 0109', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0109', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H3T 1E2', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'contacts': [{'name': 'Site 0009', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0009', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '7510032', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'contacts': [{'name': 'Site 0105', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0105', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8420383', 'city': 'Santiago', 'state': 'Santiago Metropolitan', 'country': 'Chile', 'contacts': [{'name': 'Site 0005', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0005', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8330023', 'city': 'Santiago', 'country': 'Chile', 'contacts': [{'name': 'Site 0163', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0163', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '760032', 'city': 'Cali', 'country': 'Colombia', 'contacts': [{'name': 'Site 0052', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0052', 'geoPoint': {'lat': 3.43054, 'lon': -76.5199}}, {'zip': '150 06', 'city': 'Prague', 'state': 'Praha 5', 'country': 'Czechia', 'contacts': [{'name': 'Site 0147', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0147', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '656 53', 'city': 'Brno', 'country': 'Czechia', 'contacts': [{'name': 'Site 0149', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0149', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '500 05', 'city': 'Hradec Králové', 'country': 'Czechia', 'contacts': [{'name': 'Site 0150', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0150', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '00290', 'city': 'Helsinki', 'state': 'Etelä-Suomen Lääni', 'country': 'Finland', 'contacts': [{'name': 'Site 0044', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0044', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'zip': '20521', 'city': 'Turku', 'country': 'Finland', 'contacts': [{'name': 'Site 0029', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0029', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'zip': '01640', 'city': 'Vantaa', 'country': 'Finland', 'contacts': [{'name': 'Site 0060', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0060', 'geoPoint': {'lat': 60.29414, 'lon': 25.04099}}, {'zip': '59020', 'city': 'Lille', 'state': 'Nord', 'country': 'France', 'contacts': [{'name': 'Site 0083', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0083', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '33076', 'city': 'Boredeaux', 'country': 'France', 'contacts': [{'name': 'Site 0080', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0080'}, {'zip': '94805', 'city': 'Villejuif', 'country': 'France', 'contacts': [{'name': 'Site 0028', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0028', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '07747', 'city': 'Jena', 'state': 'Thuringia', 'country': 'Germany', 'contacts': [{'name': 'Site 0025', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0025', 'geoPoint': {'lat': 50.92878, 'lon': 11.5899}}, {'zip': '20251', 'city': 'Hamburg', 'country': 'Germany', 'contacts': [{'name': 'Site 0026', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0026', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '44649', 'city': 'Herne', 'country': 'Germany', 'contacts': [{'name': 'Site 0014', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0014', 'geoPoint': {'lat': 51.5388, 'lon': 7.22572}}, {'zip': '81675', 'city': 'München', 'country': 'Germany', 'contacts': [{'name': 'Site 0027', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0027', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': 'D07 R2WY', 'city': 'Dublin', 'country': 'Ireland', 'contacts': [{'name': 'Site 0059', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0059', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': 'D24 NR0A', 'city': 'Dublin', 'country': 'Ireland', 'contacts': [{'name': 'Site 0062', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0062', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': '37126', 'city': 'Verona', 'state': 'Veneto', 'country': 'Italy', 'contacts': [{'name': 'Site 0139', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0139', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'zip': '20133', 'city': 'Milan', 'country': 'Italy', 'contacts': [{'name': 'Site 0073', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0073', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '80131', 'city': 'Napoli Campania', 'country': 'Italy', 'contacts': [{'name': 'Site 0087', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0087'}, {'zip': '135-8550', 'city': 'Koto-ku', 'state': 'Tokyo', 'country': 'Japan', 'contacts': [{'name': 'Site 0097', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0097'}, {'zip': '930-0194', 'city': 'Toyoma', 'state': 'Toyama', 'country': 'Japan', 'contacts': [{'name': 'Site 0078', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0078'}, {'zip': '64040', 'city': 'Monterrey', 'state': 'Nuevo León', 'country': 'Mexico', 'contacts': [{'name': 'Site 0046', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0046', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '68020', 'city': 'Oaxaca City', 'country': 'Mexico', 'contacts': [{'name': 'Site 0048', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0048', 'geoPoint': {'lat': 17.06025, 'lon': -96.72544}}, {'zip': '72424', 'city': 'Puebla City', 'country': 'Mexico', 'contacts': [{'name': 'Site 0122', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0122', 'geoPoint': {'lat': 19.04778, 'lon': -98.20723}}, {'zip': '14080', 'city': 'Tlalpan', 'country': 'Mexico', 'contacts': [{'name': 'Site 0049', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0049', 'geoPoint': {'lat': 19.29513, 'lon': -99.16206}}, {'zip': '14080', 'city': 'Tlalpan', 'country': 'Mexico', 'contacts': [{'name': 'Site 0108', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0108', 'geoPoint': {'lat': 19.29513, 'lon': -99.16206}}, {'zip': '14080', 'city': 'Tlalpan', 'country': 'Mexico', 'contacts': [{'name': 'Site 0118', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0118', 'geoPoint': {'lat': 19.29513, 'lon': -99.16206}}, {'zip': '400015', 'city': 'Cluj-Napoca', 'country': 'Romania', 'contacts': [{'name': 'Site 0103', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0103', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '200347', 'city': 'Craiova', 'country': 'Romania', 'contacts': [{'name': 'Site 0161', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0161', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '700483', 'city': 'Iași', 'country': 'Romania', 'contacts': [{'name': 'Site 0100', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0100', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '550082', 'city': 'Sibiu', 'country': 'Romania', 'contacts': [{'name': 'Site 0101', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0101', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}, {'zip': '06351', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi [Seoul]', 'country': 'South Korea', 'contacts': [{'name': 'Site 0112', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0112', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'state': 'Seoul-teukbyeolsi', 'country': 'South Korea', 'contacts': [{'name': 'Site 0017', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0017', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '120-752', 'city': 'Seoul', 'country': 'South Korea', 'contacts': [{'name': 'Site 0167', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0167', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'contacts': [{'name': 'Site 0013', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0013', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28050', 'city': 'Madrid', 'country': 'Spain', 'contacts': [{'name': 'Site 0091', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0091', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'contacts': [{'name': 'Site 0043', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0043', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '7000', 'city': 'Chur', 'country': 'Switzerland', 'contacts': [{'name': 'Site 0054', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0054', 'geoPoint': {'lat': 46.84986, 'lon': 9.53287}}, {'zip': '9007', 'city': 'Sankt Gallen', 'country': 'Switzerland', 'contacts': [{'name': 'Site 0055', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0055', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'zip': '8091', 'city': 'Zurich', 'country': 'Switzerland', 'contacts': [{'name': 'Site 0056', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0056', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'zip': 'CF14 2TL', 'city': 'Cardiff', 'country': 'United Kingdom', 'contacts': [{'name': 'Site 0057', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0057', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'EC1A 7BE', 'city': 'London', 'country': 'United Kingdom', 'contacts': [{'name': 'Site 0019', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0019', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW3 6JJ', 'city': 'London', 'country': 'United Kingdom', 'contacts': [{'name': 'Site 0063', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0063', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'country': 'United Kingdom', 'contacts': [{'name': 'Site 0020', 'role': 'CONTACT'}], 'facility': 'Local Institution - 0020', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}], 'centralContacts': [{'name': 'BMS Clinical Trials Contact Center www.BMSClinicalTrials.com', 'role': 'CONTACT', 'email': 'Clinical.Trials@bms.com', 'phone': '855-907-3286'}, {'name': 'First line of the email MUST contain the NCT# and Site#', 'role': 'CONTACT'}], 'overallOfficials': [{'name': 'Bristol-Myers Squibb', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bristol-Myers Squibb'}]}, 'ipdSharingStatementModule': {'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'See plan description', 'ipdSharing': 'YES', 'description': "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html", 'accessCriteria': 'See plan description'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'BioNTech SE', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}